Literature DB >> 14641079

Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats.

N Karachalias1, R Babaei-Jadidi, N Ahmed, P J Thornalley.   

Abstract

The accumulation of AGEs (advanced glycation end products) in diabetes mellitus has been implicated in the biochemical dysfunction associated with the chronic development of microvascular complications of diabetes--nephropathy, retinopathy and peripheral neuropathy. We investigated the concentrations of fructosyl-lysine and AGE residues in protein extracts of renal glomeruli, retina, peripheral nerve and plasma protein of streptozotocin-induced diabetic rats and normal healthy controls. Glycation adducts were determined by LC with tandem MS detection. In diabetic rats, the fructosyl-lysine concentration was increased markedly in glomeruli, retina, sciatic nerve and plasma protein. The concentrations of N (epsilon)-carboxymethyl-lysine and N (epsilon)-carboxyethyl-lysine were increased in glomeruli, sciatic nerve and plasma protein, and N(epsilon)-carboxymethyl-lysine also in the retina. Hydroimidazolone AGEs derived from glyoxal, methylglyoxal and 3-deoxylglucosone were major AGEs quantitatively. They were increased in the retina, nerve, glomeruli and plasma protein. AGE accumulation in renal glomeruli, retina, peripheral nerve and plasma proteins is consistent with a role for AGEs in the development of nephropathy, retinopathy and peripheral neuropathy in diabetes. High-dose therapy with thiamine and Benfotiamine suppressed the accumulation of AGEs, and is a novel approach to preventing the development of diabetic complications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14641079     DOI: 10.1042/bst0311423

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  37 in total

1.  Characterisation of glyoxalase I in a streptozocin-induced mouse model of diabetes with painful and insensate neuropathy.

Authors:  M M Jack; J M Ryals; D E Wright
Journal:  Diabetologia       Date:  2011-06-03       Impact factor: 10.122

Review 2.  Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.

Authors:  Megan Jack; Douglas Wright
Journal:  Transl Res       Date:  2012-01-10       Impact factor: 7.012

3.  Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina.

Authors:  Q Wang; F Pfister; A Dorn-Beineke; F vom Hagen; J Lin; Y Feng; H P Hammes
Journal:  Diabetologia       Date:  2010-03-26       Impact factor: 10.122

4.  Plate-based Large-scale Cultivation of Caenorhabditis elegans: Sample Preparation for the Study of Metabolic Alterations in Diabetes.

Authors:  Katharina Kohl; Thomas Fleming; Kübra Acunman; Hans-Peter Hammes; Michael Morcos; Andrea Schlotterer
Journal:  J Vis Exp       Date:  2018-08-24       Impact factor: 1.355

5.  Effects of Nigella sativa and its major constituent, thymoquinone on sciatic nerves in experimental diabetic neuropathy.

Authors:  Mehmet Kanter
Journal:  Neurochem Res       Date:  2007-08-23       Impact factor: 3.996

Review 6.  Evidence for altered thiamine metabolism in diabetes: Is there a potential to oppose gluco- and lipotoxicity by rational supplementation?

Authors:  Lukáš Pácal; Katarína Kuricová; Kateřina Kaňková
Journal:  World J Diabetes       Date:  2014-06-15

Review 7.  Too sweet: Problems of protein glycation in the eye.

Authors:  Eloy Bejarano; Allen Taylor
Journal:  Exp Eye Res       Date:  2018-08-24       Impact factor: 3.467

8.  Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.

Authors:  Y Yu; K F Hanssen; V Kalyanaraman; A Chirindel; A J Jenkins; A J Nankervis; P A Torjesen; H Scholz; T Henriksen; B Lorentzen; S K Garg; M K Menard; S M Hammad; J A Scardo; J R Stanley; M Wu; A Basu; C E Aston; T J Lyons
Journal:  BJOG       Date:  2012-08-20       Impact factor: 6.531

9.  Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function.

Authors:  Antonia G Miller; Genevieve Tan; Katrina J Binger; Raelene J Pickering; Merlin C Thomas; Ram H Nagaraj; Mark E Cooper; Jennifer L Wilkinson-Berka
Journal:  Diabetes       Date:  2010-09-17       Impact factor: 9.461

10.  Hyperglycemia impairs proteasome function by methylglyoxal.

Authors:  Markus A Queisser; Dachun Yao; Sven Geisler; Hans-Peter Hammes; Günter Lochnit; Erwin D Schleicher; Michael Brownlee; Klaus T Preissner
Journal:  Diabetes       Date:  2009-12-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.